Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Tax Provisions (2021 - 2025)

Apellis Pharmaceuticals (APLS) has 5 years of Tax Provisions data on record, last reported at $313000.0 in Q4 2025.

  • For Q4 2025, Tax Provisions rose 19.47% year-over-year to $313000.0; the TTM value through Dec 2025 reached $1.7 million, up 47.43%, while the annual FY2025 figure was $1.7 million, 48.19% up from the prior year.
  • Tax Provisions reached $313000.0 in Q4 2025 per APLS's latest filing, down from $602000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.4 million in Q4 2023 and bottomed at -$1.5 million in Q4 2022.
  • Average Tax Provisions over 5 years is $355823.5, with a median of $341000.0 recorded in 2025.
  • Peak YoY movement for Tax Provisions: crashed 517.9% in 2022, then skyrocketed 308.77% in 2025.
  • A 5-year view of Tax Provisions shows it stood at $352000.0 in 2021, then plummeted by 517.9% to -$1.5 million in 2022, then surged by 196.74% to $1.4 million in 2023, then tumbled by 81.59% to $262000.0 in 2024, then increased by 19.47% to $313000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $313000.0 in Q4 2025, $602000.0 in Q3 2025, and $466000.0 in Q2 2025.